The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
Zacks.com on MSN1d
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's DrugThe EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ...
We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...
Seeking Alpha on MSN5d
Biogen, Eisai Alzheimer’s drug review delayed in EUBiogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
The Payment Card Industry Data Security Standard’s 4.0 requirements are designed to protect card information from theft or ...
Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback